Xtant Medical (XTNT) to Release Earnings on Monday

Xtant Medical (NYSEAMERICAN:XTNT) is expected to post its Q1 2025 quarterly earnings results after the market closes on Monday, May 12th. Analysts expect Xtant Medical to post earnings of ($0.02) per share and revenue of $30.65 million for the quarter.

Xtant Medical Trading Down 6.0 %

Shares of XTNT opened at $0.50 on Friday. The firm has a market cap of $70.16 million, a price-to-earnings ratio of -3.88 and a beta of 0.35. Xtant Medical has a fifty-two week low of $0.33 and a fifty-two week high of $0.85. The firm has a 50 day moving average price of $0.47 and a 200-day moving average price of $0.50. The company has a debt-to-equity ratio of 0.42, a quick ratio of 0.88 and a current ratio of 2.12.

Xtant Medical Company Profile

Xtant Medical Holdings, Inc provides regenerative medicine products and medical devices for orthopedic and neurological surgeons. It offers OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSelect DBM Putty to mold into any shape and compressed into bony voids; OsteoSelect PLUS DBM Putty to deliver handling properties and ensure patient safety through validated terminal sterilization; 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone; OsteoFactor, a processed allograft that contains retained growth factors found within the endosteum layer of allograft bone; OsteoVive Plus, a growth factor enriched cellular bone matrix; and nanOss family of products that provide osteoconductive nano-structured hydroxyapatite and an engineered extracellular matrix bioscaffold collagen carrier.